Bingyuan Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bingyuan Ji has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Yili Wu
Center for Geriatric Medicine, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging and The First-Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China; Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou 325000, Zhejiang, China
2 shared publications - Bo Bai
Neurobiology Institute, Jining Medical University, Jining, Shandong 272067, P.R. China
1 shared publication Chuanxin Liu
School of Mental Health, Shandong Key Laboratory of Behavioral Medicine, Jining Medical University, No. 133 Hehua Road, Jining, PR China
1 shared publication- Gongying Li
Department of Mental Health, Jining Medical University, Jining, 272000, China
1 shared publication Guangyi Bao
School of Mental Health, Shandong Key Laboratory of Behavioral Medicine, Jining Medical University, No. 133 Hehua Road, Jining, PR China
1 shared publication- Hai Lu
Fudan University, Jining Medical University, China
1 shared publication
Latest Publications
- Top Cited Papers
- 1 February 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 244, 196-208
Predictors of depressive symptoms in college students: A systematic review and meta-analysis of cohort studies
- 1 February 2019
- Published by Elsevier in Journal of Affective Disorders
- Vol. 244, 196-208
Top Cited PapersPredictors of depressive symptoms in college students: A systematic review and meta-analysis of cohort studies
- Open Access
- 12 September 2018
- Published by Springer Nature in Clinical Epigenetics
- Vol. 10 (1) , 1-9
HDAC4 in ischemic stroke: mechanisms and therapeutic potential
Stroke is one of the leading causes of death and disability worldwide, and the majority of the cases are ischemic stroke. However, it still lacks effective treatment except for thrombolytic therapy in an extremely narrow time window. Increased evidence suggests that histone deacetylase 4 (HDAC4) was dysregulated in ischemic stroke, which plays a key role in the pathogenesis of ischemic stroke and post-stroke recovery by affecting neuronal death, angiogenesis, and neurogenesis. Therefore, we aim to review the dysregulation of HDAC4 in ischemic stroke and the role of dysregulated HDAC4 in the pathogenesis of ischemic stroke. Furthermore, the therapeutic potential of modulating HDAC4 in ischemic stroke is discussed.
- 12 September 2018
- Published by Springer Nature in Clinical Epigenetics
- Vol. 10 (1) , 1-9
Open AccessHDAC4 in ischemic stroke: mechanisms and therapeutic potential
Stroke is one of the leading causes of death and disability worldwide, and the majority of the cases are ischemic stroke. However, it still lacks effective treatment except for thrombolytic therapy in an extremely narrow time window. Increased evidence suggests that histone deacetylase 4 (HDAC4) was dysregulated in ischemic stroke, which plays a key role in the pathogenesis of ischemic stroke and post-stroke recovery by affecting neuronal death, angiogenesis, and neurogenesis. Therefore, we aim to review the dysregulation of HDAC4 in ischemic stroke and the role of dysregulated HDAC4 in the pathogenesis of ischemic stroke. Furthermore, the therapeutic potential of modulating HDAC4 in ischemic stroke is discussed.
- 1 November 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1863 (11) , 2719-2738
Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel β-arrestin-2–biased pathway
- 1 November 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1863 (11) , 2719-2738
Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel β-arrestin-2–biased pathway